Emel Aygören‐Pürsün
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emel Aygören‐Pürsün has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Markus Magerl
Institute of Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
4 shared publications - Konrad Bork
Department of Dermatology University Medical Center Johannes Gutenberg University Mainz Germany
2 shared publications - Chiara Nenci
CSL Behring AG Bern Switzerland
1 shared publication - Christina Weber-Chrysochoou
Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
1 shared publication - Christoph Hirche
Takeda Pharma Vertrieb GmbH & Co. KG Berlin Germany
1 shared publication - Fabian Berkemeier
IGES Institute GmbH Berlin Germany
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10) , e70737
Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack‐Free Probability and Quality of Life Over 5 Years
Hereditary angioedema (HAE) attacks are recurrent, debilitating, and potentially life‐threatening. Across the clinical program, garadacimab long‐term prophylaxis demonstrated early onset and durable, sustained protection against HAE attacks and clinically meaningful improvements in health‐related quality of life (HRQoL). HAE treatment goals include total disease control (attack‐free) and normalization of life. Predicting treatment effect may aid shared decision‐making and choice of long‐term prophylaxis. Here, we report an attack‐free probability model predicting garadacimab treatment effect beyond available Phase 3 clinical data and explore the relationship between HRQoL and attack‐free duration. A generalized mixed‐effect Poisson model was developed and validated with data from the garadacimab pivotal Phase 3 (VANGUARD) and Phase 3 open‐label extension studies. Efficacy variables, including attack‐free probabilities, were predicted for simulated populations of garadacimab‐treated patients and assessed for goodness of fit. Analysis of covariance was used to assess the relationship between Angioedema Quality of Life questionnaire scores and attack‐free duration. Model‐predicted efficacy variables adequately reflected observed clinical data with high goodness of fit (Nakagawa–Schielzeth conditional R 2 : 74.3%). Following a 1‐month attack‐free period after garadacimab initiation, patients had a 60% cumulative probability of remaining attack‐free up to Month 25 and 49% up to 5 years. HRQoL improved with increasing duration of attack‐free periods, reaching minimal to no impairment after 6 months. This attack‐free probability model suggests long‐term effects of garadacimab over a 5‐year treatment period. Patients treated with garadacimab have the potential to live attack‐free for long periods of time, with substantial HRQoL improvements.
- 9 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10) , e70737
Open AccessGaradacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack‐Free Probability and Quality of Life Over 5 Years
Hereditary angioedema (HAE) attacks are recurrent, debilitating, and potentially life‐threatening. Across the clinical program, garadacimab long‐term prophylaxis demonstrated early onset and durable, sustained protection against HAE attacks and clinically meaningful improvements in health‐related quality of life (HRQoL). HAE treatment goals include total disease control (attack‐free) and normalization of life. Predicting treatment effect may aid shared decision‐making and choice of long‐term prophylaxis. Here, we report an attack‐free probability model predicting garadacimab treatment effect beyond available Phase 3 clinical data and explore the relationship between HRQoL and attack‐free duration. A generalized mixed‐effect Poisson model was developed and validated with data from the garadacimab pivotal Phase 3 (VANGUARD) and Phase 3 open‐label extension studies. Efficacy variables, including attack‐free probabilities, were predicted for simulated populations of garadacimab‐treated patients and assessed for goodness of fit. Analysis of covariance was used to assess the relationship between Angioedema Quality of Life questionnaire scores and attack‐free duration. Model‐predicted efficacy variables adequately reflected observed clinical data with high goodness of fit (Nakagawa–Schielzeth conditional R 2 : 74.3%). Following a 1‐month attack‐free period after garadacimab initiation, patients had a 60% cumulative probability of remaining attack‐free up to Month 25 and 49% up to 5 years. HRQoL improved with increasing duration of attack‐free periods, reaching minimal to no impairment after 6 months. This attack‐free probability model suggests long‐term effects of garadacimab over a 5‐year treatment period. Patients treated with garadacimab have the potential to live attack‐free for long periods of time, with substantial HRQoL improvements.
- Open Access
Algorithms in Allergy: Hereditary Angioedema
- Open Access
Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study
Background: Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. Since head‐to‐head trials between authorized treatments are lacking, this study compares efficacy and safety of lanadelumab and intravenous plasma‐derived C1‐esterase inhibitor (pdC1‐INH i.v.) in HAE patients on long‐term prophylaxis by means of an indirect treatment comparison.Methods: Efficacy and safety of lanadelumab against pdC1‐INH i.v. were analyzed in a fully prespecified indirect comparison based on individual patient data (n = 231) from the HELP and CHANGE clinical trials. Primary and secondary efficacy endpoints were compared using a generalized linear model for count data. Confounding variables were identified a priori via systematic literature research and validated by clinical experts. Adjustment of confounders was implemented using a conditional regression model.Results: Lanadelumab showed a statistically significant improvement in reduction of HAE attack rates compared to pdC1‐INH i.v. across multiple endpoints: Monthly attack rate of patients treated with lanadelumab was less than half compared to pdC1‐INH i.v. (Rate ratio: 0.486; 95% CI: 0.253, 0.932). Monthly rate of laryngeal attacks was found to be five times lower for lanadelumab (Rate ratio: 0.2; 95% CI: 0.044, 0.915) and monthly rate of acute treated HAE attacks among lanadelumab patients was about one third of the attack rate of pdC1‐INH i.v. patients (Rate ratio: 0.366; 95% CI: 0.185, 0.727).Conclusion: This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1‐INH i.v.
Open AccessPatient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study
Background: Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. Since head‐to‐head trials between authorized treatments are lacking, this study compares efficacy and safety of lanadelumab and intravenous plasma‐derived C1‐esterase inhibitor (pdC1‐INH i.v.) in HAE patients on long‐term prophylaxis by means of an indirect treatment comparison.Methods: Efficacy and safety of lanadelumab against pdC1‐INH i.v. were analyzed in a fully prespecified indirect comparison based on individual patient data (n = 231) from the HELP and CHANGE clinical trials. Primary and secondary efficacy endpoints were compared using a generalized linear model for count data. Confounding variables were identified a priori via systematic literature research and validated by clinical experts. Adjustment of confounders was implemented using a conditional regression model.Results: Lanadelumab showed a statistically significant improvement in reduction of HAE attack rates compared to pdC1‐INH i.v. across multiple endpoints: Monthly attack rate of patients treated with lanadelumab was less than half compared to pdC1‐INH i.v. (Rate ratio: 0.486; 95% CI: 0.253, 0.932). Monthly rate of laryngeal attacks was found to be five times lower for lanadelumab (Rate ratio: 0.2; 95% CI: 0.044, 0.915) and monthly rate of acute treated HAE attacks among lanadelumab patients was about one third of the attack rate of pdC1‐INH i.v. patients (Rate ratio: 0.366; 95% CI: 0.185, 0.727).Conclusion: This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1‐INH i.v.
- Open Access
- 10 June 2020
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 31 (8) , 974-989
Hereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries
Background/Methods: At a consensus meeting in August 2018, pediatricians and dermatologists from German‐speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE‐C1‐INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE‐C1‐INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life‐threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This article provides recommendations for developing appropriate treatment strategies in the management of HAE‐C1‐INH in pediatric patients in German‐speaking countries. An overview of available drugs in this age‐group is provided, together with their approval status, and study results obtained in adults and pediatric patients.Results/Conclusion: Currently, plasma‐derived C1 inhibitor concentrates have the broadest approval status and are considered the best available option for on‐demand treatment of HAE‐C1‐INH attacks and for short‐ and long‐term prophylaxis across all pediatric age‐groups in German‐speaking countries. For on‐demand treatment of children aged 2 years and older, recombinant C1‐INH and bradykinin‐receptor antagonist icatibant are alternatives. For long‐term prophylaxis in adolescents, the parenteral kallikrein inhibitor lanadelumab has recently been approved and can be recommended due to proven efficacy and safety.
- 10 June 2020
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 31 (8) , 974-989
Open AccessHereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries
Background/Methods: At a consensus meeting in August 2018, pediatricians and dermatologists from German‐speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE‐C1‐INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE‐C1‐INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life‐threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This article provides recommendations for developing appropriate treatment strategies in the management of HAE‐C1‐INH in pediatric patients in German‐speaking countries. An overview of available drugs in this age‐group is provided, together with their approval status, and study results obtained in adults and pediatric patients.Results/Conclusion: Currently, plasma‐derived C1 inhibitor concentrates have the broadest approval status and are considered the best available option for on‐demand treatment of HAE‐C1‐INH attacks and for short‐ and long‐term prophylaxis across all pediatric age‐groups in German‐speaking countries. For on‐demand treatment of children aged 2 years and older, recombinant C1‐INH and bradykinin‐receptor antagonist icatibant are alternatives. For long‐term prophylaxis in adolescents, the parenteral kallikrein inhibitor lanadelumab has recently been approved and can be recommended due to proven efficacy and safety.